Prevalencia de obesidad en una cohorte de pacientes con artritis psoriásica y factores asociados

C.A. Zaffarana; E.E. Schneeberger; J. Gallino Yanzi; O. Cerda; M. Landi; G. Citera

doi:10.47196/rar.v28i2.561

C.A. Zaffarana Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
E.E. Schneeberger Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
J. Gallino Yanzi Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
O. Cerda Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
M. Landi Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
G. Citera Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v28i2.561

Palabras clave: obesidad, prevalencia, prevalencia psoriásica

Resumen

Se ha observado elevada prevalencia de obesidad en pacientes con Artritis Psoriásica (APs). También, ha sido descripta asociación con una mayor severidad de psoriasis cutánea, pero su relación con la severidad de la APs ha sido menos estudiada. Objetivos: Evaluar la prevalencia de obesidad en una cohorte de pacientes con APs y su asociación con características sociodemográﬁcas y clínicas de la enfermedad.

Citas

I. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl. 2):ii14–7.

II. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33(11):2167-72.

III. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72(3):211-6.

IV. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011;63(2):195-202.

V. Kumar S, Han J, Li T Qureshi AA. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2013;27(10)1293-8.

VI. Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012;71(8):1273-7.

VII. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012;2:e54

VIII. Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2014;28(7):907-14.

IX. Jensen P, Zachariae C, Christensen R, Geiker NR, Schaadt BK, Stender S, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 2013;149(7):795-801.

X. Zhang C, Zhu KJ, Zheng HF, Cui Y, Zhou FS, Chen YL, et al. The effect of overweight and obesity on psoriasis patients in Chinese Han population: a hospital-based study. J Eur Acad Dermatol Venereol 2011;25(1):87-91.

XI. T aylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.

XII. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38(1):38-43.

XIII. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69(8):1441-7

XIV. Citera G, Maldonado Cocco J, Moroldo M, Burgos-Vargas R, Anaya J, López I, et al. Validación de la versión en español de los cuestionarios de capacidad funcional (BASFI) y actividad de la enfermedad (BASDAI) en pacientes con Espondilitis Anquilosante en cuatro países latinoamericanos. Rev Arg Reumatol 1999;10(1):25.

XV. G arret S, Jenkinson T, KennedyLG, Whitelock H, Gaisfold P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Anlylosing Spondylitis DiseaseActivity Index. J Rheumatol 1994;21(12):2286-91.

XVI. C oates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010;62(7):965-9.

XVII. Citera G, Arriola MS, Maldonado Cocco JA, Rosemffet MA, Goñi MA, Spindler A, et al. Validation and cross cultural adaptation of an Argentine Spanish version of the health assessment questionnaire disability index. J Clin Rheumatol 2004;10(3):110-5.

XVIII. Calin A, Garret S, Whitelock H, Kennedy LG, O´Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Anlylosing Spondylitis Functional Index. J Rheumatol 1994;21(12):2281-5.

XIX. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210-6.

XX. M cKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63(2):162-9.

XXI. F redriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157(4):238-44.

XXII. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62(2):127-32.

XXIII. Moll J y Wright V. Psoriatic Arthritis. Semin Arthritis Rheum. 1973;3(1):55-78.

XXIV. Ritchlin CT, Kavanaugh A Gladman, DD, Mease PJ, Helliwell P, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68(9):1387-1394.

XXV. INDEC, Ministerio de Salud, Presidencia de la Nación Argentina. Tercera encuesta Nacional de factores de riesgo para enfermedades no transmisibles. 10 de Julio de 2015. Buenos Aires, Argentina. ISBN: 978-950-38-0218-2.

XXVI. S tatistics Canada. Canadian Community Health Survey (CCHS) Cycle 3.1 (2005) Public Use Microdata File (PUMF) User Guide. Ottawa: Statistics Canada, 2006.

XXVII. Hubert HB, Feinleib M, Macnamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67(5):968-977.

XXVIII. N eogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am 2013;39(1):1-19.

XXIX. S andell LJ. Obesity and osteoarthritis: is leptin the link? Arthritis Rheum 2009;60(10):2858-2860.

XXX. D i Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013;65(1):141-7.

XXXI. Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis 2014;73(6):1157-62.

XXXII. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008;158(5):1134-5.

XXXIII. T akahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159(5):1207-8.

XXXIV. Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 2013;72(12):1956-61.